Kapvay
NDC Package 59212-659-60

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Kapvay is a medication used alone or with other medications to treat attention deficit hyperactivity disorder (ADHD) as part of a total treatment plan, including psychological, social, and other treatments. Marketed by Concordia Pharmaceuticals Inc., this product is identified by NDC 59212-659 and is authorized under FDA application NDA022331.

Identification & Billing

NDC Package Code
59212-659-60
Package Description
60 TABLET, EXTENDED RELEASE in 1 BOTTLE
Product Code
59212-659
11-Digit Billing Format
59212065960

Clinical Specifications

Proprietary Name
Kapvay
Dosage Form
-
Usage Information
This medication is used alone or with other medications to treat attention deficit hyperactivity disorder (ADHD) as part of a total treatment plan, including psychological, social, and other treatments.

Regulatory & Marketing

Labeler Name
Concordia Pharmaceuticals Inc.
FDA Application #
NDA022331
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
12-09-2010
End Marketing Date
03-17-2018
Listing Expiration
03-17-2018
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 59212-659-60 identifies a specific commercial package of 60 tablet, extended release in 1 bottle of Kapvay, labeled by Concordia Pharmaceuticals Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Concordia Pharmaceuticals Inc. on December 09, 2010. The current certification is valid through March 17, 2018.

What are the primary indications for this medication?

This medication is used alone or with other medications to treat attention deficit hyperactivity disorder (ADHD) as part of a total treatment plan, including psychological, social, and other treatments.

How is this Concordia Pharmaceuticals Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 59212065960. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
59212-659-60
11-Digit CMS (5-4-2)
59212-0659-60

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.